Form 4: Natera Co-Founder Jonathan Sheena Sells Shares Under 10b5-1 Trading Plan

Jonathan Sheena, co-founder of Natera, Inc., sold a portion of his common stock holdings on August 12, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 12, 2024, Jonathan Sheena, a co-founder of Natera, Inc. (NTRA), sold shares of common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 12, 2023.
• A total of 2,700 shares were sold in multiple transactions at varying weighted average prices.
• The prices ranged from $112.29 to $115.7 per share.
• Following the reported transactions, Sheena directly owns 299,441 shares of Natera common stock.
• Sheena also indirectly owns 68,582 shares through the Caraluna 1 Trust and 68,582 shares through the Caraluna 2 Trust, both held for the benefit of his minor children, for which he disclaims beneficial ownership.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a routine disclosure of insider selling under a pre-arranged plan, which doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The sales were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• While the sales are under a 10b5-1 plan, any insider selling can sometimes be perceived negatively by the market.

Future Outlook

The document does not contain any specific forward-looking statements regarding Natera's future performance.

Industry Context

Insider sales are a common occurrence in publicly traded companies. The use of a 10b5-1 trading plan is a standard practice to avoid accusations of trading on inside information. Investors often monitor insider transactions for signals about a company's prospects, but sales under a pre-arranged plan are generally viewed as less informative.

Comparison to Industry Standards

• Comparing insider selling activity at Natera to similar companies in the genetic testing or diagnostics industry would require analyzing Form 4 filings for companies like Exact Sciences (EXAS), Invitae (NVTA), or Guardant Health (GH).

Stakeholder Impact

• The sale of shares by a co-founder could have a minor psychological impact on shareholders, but the existence of a 10b5-1 plan mitigates concerns about insider information.

Key Dates